<DOC>
	<DOCNO>NCT00043810</DOCNO>
	<brief_summary>Patients Acute Myelogenous Leukemia Myelodysplastic able achieve complete remission fail achieve prolong disease-free survival . High dose chemotherapy autologous bone marrow transplantation show effective group patient hematopoietic recovery slow , infectious bleeding complication common . The delay hematopoietic recover accentuate use purge technique . This novel purging approach autologous stem cell transplantation patient Acute Myelogenous Leukemia Myelodysplastic syndrome allow rapid engraftment low relapse rate therefore improve therapeutic outcome</brief_summary>
	<brief_title>Study Gelonin Purging Autologous Stem Cells Transplantation</brief_title>
	<detailed_description>Treatment : The HuM195-Gelonin conjugate design target leukemia cell destroy . This treatment divide 3 part . Part I : MOBILIZATION STEM CELL COLLECTION : This process allow collection autologous stem cell ( cell use transplant ) . All participant receive drug idarubicin vein 3 day together cytarabine vein 3 day . This follow injection filgrastim ( Neupogen ) skin twice day white count recover stem cell collect . During process , number stem cell blood measure . When number cell reach certain level , participant go collection procedure know apheresis . The apheresis procedure include collect blood large catheter place collarbone arm assistance device know cell separator . This device separate stem cell rest blood return rest blood participant . The procedure usually do outpatient take 4-5 hour perform . Most patient collect enough cell transplant 1 2 procedure . In study , maximum 5 procedure allow . Participants unable enough cell collect take part study procedure , take study offer alternative standard investigational therapy . Participants able leave hospital physician approval . They monitor daily basis white blood cell count recover ( usually 4-5 week ) . The stem cell collection do either inpatient outpatient procedure depend participant 's condition . Part II : PURGING PROCEDURE : The stem cell collect apheresis procedure treat laboratory Hum195/Gelonin conjugate . This procedure know purge study learn treatment stem cell HuM195/Gelonin conjugate eliminate leukemia cell without damage normal stem cell . Since best dose HuM195/Gelonin conjugate purge know , cell participant study receive 1 3 different dos HuM195/Gelonin . The dose HuM195/Gelonin cell receive decide randomly accord experience participant treat earlier study . The first 3 participant study receive cell treat HuM195/Gelonin After cell treat , frozen future use high dose busulfan treatment give . As safety measure , participant need proportion untreated stem cell back . These come original stem cell harvest bone marrow harvest . Part III : HIGH DOSE FLUDARABINE/BUSULFAN WITH AUTOLOGOUS STEM CELL TRANSPLANT : All participant enough cell treat HuM195-Gelonin conjugate receive busulfan . Busulfan give vein day four day . It give together fludarabine vein day 4 day . Three day participant receive last dose busulfan , receive previously store stem cell blood transfusion . All participant receive supportive care . This include antibiotic , transfusion blood product , extra nutrient , pain medication , medication quicken recovery white blood cell . Participants study least 12 month stem cell transplant come regular check ups . All participant busulfan blood level check specific time , busulfan infusion . On occasion blood level may draw . Levels drawn small needle place hand arm patient remove last busulfan blood draw . The busulfan dose administer MAY modify accord level prevent side effect . Two teaspoon blood drawn measurement time . Participants remain hospital 4-6 week outpatient 1 3 month . After participant leave Medical Center Area , see transplant center every 3 6 month 2 year . This investigational study . The FDA authorize use HuM195-Gelonin conjugate research . Fludarabine previously approve treatment chronic lymphocytic leukemia FDA . The injectable solution busulfan new preparation approve FDA allogeneic transplantation chronic myelogenous leukemia ( CML ) . The use drug study investigational . Up 24 patient enrol study . All enrol UTMDACC .</detailed_description>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>GEL protein , Gelonium multiflorum</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Patients AML , RAEBt , RAEB , CMML first remission poor prognosis cytogenetic abnormality ( i.e : deletion chromosome 5 , 7 , 20 ; trisomy 8 , t9,22,11q23 abnormality complex karyotype ) . * Patients AML , RAEBt , RAEB , CMML second subsequent remission . Remission define ANC &gt; 1.5 x 109/Lt ; Platelet count &gt; 100 x 109/Lt , red cell transfusion independence . Male female provide write informed consent . Tumor cell must &gt; 80 % CD33 positive flow cytometry . For woman childbearing potential ( i.e. , exclude postmenopausal woman , woman surgically sterilize ) , adequate birth control method must use . Acceptable birth control method limit oral contraceptive , implant , diaphragm , IUD spermicide use condom ) No chemotherapy two week prior enter study . No evidence residual toxic effect prior chemotherapy . Patients proven bacterial infection eligible resolution infection ( patient afebrile , steroid ) . Patients active fungal infection eligible evidence response antifungal medication document fever exceed 38C . Must least 5 x 106 CD34+ peripheral blood stem cell collect . All patient le 7 x 106 CD34+ cells/kg collect , bone marrow harvest serve backup . A minimum 1 x 106 CD34+ cells/kg unpurged bone marrow 2 x 106 CD34+ cells/kg unpurged peripheral blood need store backup eligible protocol . Patients must bilirubin less 2.0 , transaminases less 4 x upper limit normal . Pulmonary function test &gt; 50 % predict DLCO , FVC FEV1 No active uncontrolled infection No active CNS disease No uncontrolled arrythmias Zubrod Performance Status less equal 2 Active CNS disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>AML</keyword>
	<keyword>MDS</keyword>
	<keyword>Gelonin</keyword>
	<keyword>Purging</keyword>
	<keyword>Transplant</keyword>
	<keyword>Peripheral Stem Cell</keyword>
</DOC>